ChiCTR1900021561 版本V1.0 版本创建时间2019/02/27 18:15:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900021561 

最近更新日期:

Date of Last Refreshed on:

2019-02-27 18:12:34 

注册时间:

Date of Registration:

2019-02-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

口服渗透性缓泻剂在预防腹部手术术后肠梗阻发生中的作用研究:前瞻性、单中心、空白对照试验

Public title:

The role of oral permeable laxatives in the prevention of intestinal obstruction after abdominal surgery: A prospective, single center, blank control trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

口服渗透性缓泻剂在预防腹部手术术后肠梗阻发生中的作用研究:前瞻性、单中心、空白对照试验

Scientific title:

The role of oral permeable laxatives in the prevention of intestinal obstruction after abdominal surgery: A prospective, single center, blank control trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

郭春宝 

研究负责人:

郭春宝 

Applicant:

Chunbao Guo 

Study leader:

Chunbao Guo 

申请注册联系人电话:

Applicant telephone:

+86 13032386618

研究负责人电话:

Study leader's telephone:

+86 13032386618

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

guochunbao@foxmail.com

研究负责人电子邮件:

Study leader's E-mail:

guochunbao@foxmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区中山二路136号

研究负责人通讯地址:

重庆市渝中区中山二路136号

Applicant address:

136 Second Zhongshan Road, Chongqing, China

Study leader's address:

136 Second Zhongshan Road, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

400014

研究负责人邮政编码:

Study leader's postcode:

400014

申请人所在单位:

重庆医科大学附属儿童医院

Applicant's institution:

Children’s Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属儿童医院

Affiliation of the Leader:

Children’s Hospital of Chongqing Medical University

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属儿童医院

Primary sponsor:

Children’s Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区中山二路136号

Primary sponsor's address:

136 Second Zhongshan Road, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

重庆

Country:

China

Province:

Chongqing

City:

Chongqing

单位(医院):

重庆医科大学附属儿童医院

具体地址:

渝中区中山二路136号

Institution
hospital:

Children’s Hospital of Chongqing Medical University

Address:

136 Second Zhongshan Road

经费或物资来源:

自筹

Source(s) of funding:

No

Target disease:

intestinal obstruction

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过研究渗透性缓泻剂在预防腹部手术后肠梗阻发生中的作用,为术后肠梗阻的发生提供可靠的预防措施。  

Objectives of Study:

By studying the role of osmotic laxative in preventing intestinal obstruction after abdominal surgery, this paper will provide reliable preventive measures for postoperative intestinal obstruction.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄0-18岁;
2.既往有明确腹部手术史。

Inclusion criteria

1.Aged 0-18 years;
2.Previous definite history of abdominal surgery.

排除标准:

1.合并其他疾病者;
2.有择期再次手术计划者;
3.已有肠梗阻发生者;
4.术后有并发症发生的患儿。

Exclusion criteria:

1. Patients with other diseases;
2. Have a plan for elective reoperation;
3. Intestinal obstruction has occurred;
4. Children with postoperative complications.

研究实施时间:

Study execute time:

From 2019-06-01 00:00:00 To 2023-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-06-01 00:00:00 To 2023-06-01 00:00:00  

干预措施:

Interventions:

组别:

缓泻剂组

样本量:

100

Group:

laxative group

Sample size:

干预措施:

口服缓泻剂+常规治疗

干预措施代码:

Intervention:

laxative management,Conventional treatment

Intervention code:

组别:

空白对照组

样本量:

100

Group:

Blank control group

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

Conventional treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

china 

Province:

chongqing 

City:

 

单位(医院):

重庆医科大学附属儿童医院 

单位级别:

三级甲等医院 

Institution
hospital:

Children’s Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肠梗阻发生率

指标类型:

主要指标

Outcome:

Incidence of intestinal obstruction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠梗阻手术干预情况

指标类型:

次要指标

Outcome:

Surgical intervention for intestinal obstruction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由收治医生使用计算机程序实现随机化。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization was performed by the attending physician using a computer program.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

No

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

文章发布(2024年)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish of paper (2024 year)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-02-27 18:12:34